APPENDICURE

Innovations in the Treatment of Appendix Cancer

BLOG

Category: Education

  • Appendix Cancer Guidelines and the PSM Consortium’s Trainee-Led Update Model

    Appendix cancer guidelines shape almost every decision a patient and family will face: when to operate, when to refer to a peritoneal surface malignancy center, when to use systemic chemotherapy, when to watch and wait. The quality of those guidelines depends on how the people writing them actually work together. A new paper in Annals…

  • CRS-HIPEC Surgeon Volume: Why the Whole Team Matters

    Why CRS-HIPEC Surgeon Volume Is Only Part of the Story CRS-HIPEC surgeon volume has long been the metric patients are told to focus on when picking a treatment center. That advice is correct, and it is incomplete. A new study from Johns Hopkins, published in Annals of Surgical Oncology in 2026, shows that the anesthesiologist’s…

  • What a New AI Biomarker Could Mean for Appendix Cancer Patients

    APPENDIX CANCER AI BIOMARKER RESEARCH, IN PLAIN LANGUAGE A new appendix cancer AI biomarker concept is making its way through the research world. A preprint from MD Anderson, posted in May 2026, describes a deep learning model called TmSNet… A new preprint from researchers at MD Anderson, posted in May 2026, describes a deep learning…

  • What 916 Tumors Are Telling Us About Treating Appendix Cancer

    RESEARCH SPOTLIGHT A new study using next-generation sequencing finds that more than 1 in 5 appendix cancer samples carry mutations that could be matched to existing or emerging drugs. The catch: it depends on the subtype, and most patients still aren’t getting tested. If you or someone you love has been diagnosed with appendix cancer,…

  • How a New Cancer Drug Actually Gets Approved

    How a New Cancer Drug Actually Gets Approved

    APPENDICURE  ·  PATIENT EDUCATION And why, for a rare cancer community, every approval somewhere else is a small lesson in what to watch for. If you spend any time in appendix cancer communities, you have probably seen the same pattern. Someone shares a news article about a promising new drug. The headline sounds like a…

  • Right to Try, Compassionate Use, and Early Access: What Appendix Cancer Patients Should Know

    RESEARCH SPOTLIGHT  ·  TREATMENT ACCESS When standard treatment runs out, a handful of legal pathways may open the door to investigational therapies. Here is what they actually are, how they work, and what to ask for. One of the hardest realities of a rare cancer is that promising therapies often exist for years before patients…